Search results
Results from the WOW.Com Content Network
In a study of more than 50,000 patients in the Mayo Clinic Health System https://bit.ly/37Btmhf, researchers found the effectiveness of Moderna's vaccine against infection had dropped to 76% in ...
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from a September forecast of $2.5 billion to $3.5 billion. And Moderna said ...
Thursday, Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, enabling a focus on ten prioritized products. The company ...
The Moderna news followed preliminary results from the Pfizer-BioNTech vaccine candidate, BNT162b2, with Moderna demonstrating similar efficacy, but requiring storage at the temperature of a standard medical refrigerator of 2–8 °C (36–46 °F) for up to thirty days or −20 °C (−4 °F) for up to four months, whereas the Pfizer-BioNTech ...
Pfizer and Moderna may soon begin emergency distribution of coronavirus vaccines created with genetic technology. Here's everything you need to know:How do these vaccines work? Up to now, vaccines ...
An example of one mimic miRNA therapy that demonstrated efficacy in impeding lung cancer tumor growth in mouse studies is miR-34a. [ 83 ] [ 84 ] One concerning aspect of miRNA-based therapies is the potential for the exogeneous miRNA to affect miRNA silencing mechanisms within normal body cells, thereby affecting normal cellular biochemical ...
Moderna’s management expressed stronger confidence in their pre-election strategy to focus on investments in oncology and rare diseases while reducing reliance on respiratory infectious diseases.
mRNA-4157/V940 was initially developed by Moderna starting in 2017. In May 2018, Moderna and MSD (Merck in US) announced collaboration on further development of the investigational agent. In 2019 Moderna and Merck jointly put mRNA-4157/V940 into clinical trials in combination with Merck's cancer immunotherapy drug pembrolizumab in resected ...